|
1
|
Brown JS, Amend SR, Austin RH, Gatenby RA,
Hammarlund EU and Pienta KJ: Updating the definition of cancer. Mol
Cancer Res. 21:1142–1147. 2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang H, Naghavi M, Allen C, Barber RM,
Bhutta Z, Carter AR, Casey DC, Charlson FJ, Chen A, Coates MM, et
al: Global, regional, and national life expectancy, all-cause
mortality, and cause-specific mortality for 249 causes of death,
1980-2015: A systematic analysis for the global burden of disease
study 2015. Lancet. 388:1459–1544. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Balkwill FR, Capasso M and Hagemann T: The
tumor microenvironment at a glance. J Cell Sci. 125:5591–5596.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sun H, Wang X, Wang X, Xu M and Sheng W:
The role of cancer-associated fibroblasts in tumorigenesis of
gastric cancer. Cell Death Dis. 13(874)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cacho-Díaz B, García-Botello DR,
Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sánchez E and
Herrera-Montalvo LA: Tumor microenvironment differences between
primary tumor and brain metastases. J Transl Med.
18(1)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kim G, Pastoriza JM, Condeelis JS, Sparano
JA, Filippou PS, Karagiannis GS and Oktay MH: The contribution of
race to breast tumor microenvironment composition and disease
progression. Front Oncol. 10(1022)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kim S, Kim A, Shin JY and Seo JS: The
tumor immune microenvironmental analysis of 2,033 transcriptomes
across 7 cancer types. Sci Rep. 10(9536)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shoucair I, Weber Mello F, Jabalee J,
Maleki S and Garnis C: The role of cancer-associated fibroblasts
and extracellular vesicles in tumorigenesis. Int J Mol Sci.
21(6837)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Senga SS and Grose RP: Hallmarks of
cancer-the new testament. Open Biol. 11(200358)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Xiao Y and Yu D: Tumor microenvironment as
a therapeutic target in cancer. Pharmacol Ther.
221(107753)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Babar Q, Saeed A, Tabish TA, Sarwar M and
Thorat ND: Targeting the tumor microenvironment: Potential strategy
for cancer therapeutics. Biochim Biophys Acta Mol Basis Dis.
1869(166746)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Boomgarden AC, Sheehan C and
D'Souza-Schorey C: Extracellular vesicles in the tumor
microenvironment: Various implications in tumor progression. Adv
Exp Med Biol. 1259:155–170. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Helms E, Onate MK and Sherman MH:
Fibroblast heterogeneity in the pancreatic tumor microenvironment.
Cancer Discov. 10:648–656. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang SS, Ma S, Dou H, Liu F, Zhang SY,
Jiang C, Xiao M and Huang YX: Breast cancer-derived exosomes
regulate cell invasion and metastasis in breast cancer via miR-146a
to activate cancer associated fibroblasts in tumor
microenvironment. Exp Cell Res. 391(111983)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kalluri R: The biology and function of
fibroblasts in cancer. Nat Rev Cancer. 16:582–598. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yang J, Antin P, Berx G, Blanpain C,
Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori
G, et al: Guidelines and definitions for research on
epithelial-mesenchymal transition. Nat Rev Mol Cell Biol.
21:341–352. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mahadevan D and Von Hoff DD: Tumor-stroma
interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther.
6:1186–1197. 2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Baroni S, Romero-Cordoba S, Plantamura I,
Dugo M, D'Ippolito E, Cataldo A, Cosentino G, Angeloni V, Rossini
A, Daidone MG and Iorio MV: Exosome-mediated delivery of miR-9
induces cancer-associated fibroblast-like properties in human
breast fibroblasts. Cell Death Dis. 7(e2312)2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chen B, Sang Y, Song X, Zhang D, Wang L,
Zhao W, Liang Y, Zhang N and Yang Q: Exosomal miR-500a-5p derived
from cancer-associated fibroblasts promotes breast cancer cell
proliferation and metastasis through targeting USP28. Theranostics.
11:3932–3947. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu
W, Wang D and Lou W: Exosomal miRNA-106b from cancer-associated
fibroblast promotes gemcitabine resistance in pancreatic cancer.
Exp Cell Res. 383(111543)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli
K, Andersen S, Sirera R, Camps C, Marinez I and Busund LT: The role
of tumor stroma in cancer progression and prognosis: emphasis on
carcinoma-associated fibroblasts and non-small cell lung cancer. J
Thorac Oncol. 6:209–217. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sahai E, Astsaturov I, Cukierman E,
DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR,
Hunter T, et al: A framework for advancing our understanding of
cancer-associated fibroblasts. Nat Rev Cancer. 20:174–186.
2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Affo S, Nair A, Brundu F, Ravichandra A,
Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X, et
al: Promotion of cholangiocarcinoma growth by diverse
cancer-associated fibroblast subpopulations. Cancer Cell.
39:866–882.e11. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Unterleuthner D, Neuhold P, Schwarz K,
Janker L, Neuditschko B, Nivarthi H, Crncec I, Kramer N, Unger C,
Hengstschläger M, et al: Cancer-associated fibroblast-derived WNT2
increases tumor angiogenesis in colon cancer. Angiogenesis.
23:159–177. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Monteran L and Erez N: The dark side of
fibroblasts: Cancer-associated fibroblasts as mediators of
immunosuppression in the tumor microenvironment. Front Immunol.
10(1835)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Su S, Chen J, Yao H, Liu J, Yu S, Lao L,
Wang M, Luo M, Xing Y, Chen F, et al:
CD10+GPR77+ cancer-associated fibroblasts
promote cancer formation and chemoresistance by sustaining cancer
stemness. Cell. 172:841–856.e16. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
LeBleu VS and Kalluri R: A peek into
cancer-associated fibroblasts: Origins, functions and translational
impact. Dis Model Mech. 11(dmm029447)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Norton J, Foster D, Chinta M, Titan A and
Longaker M: Pancreatic cancer associated fibroblasts (CAF):
Under-explored target for pancreatic cancer treatment. Cancers
(Basel). 12(1347)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Glabman RA, Choyke PL and Sato N:
Cancer-associated fibroblasts: Tumorigenicity and targeting for
cancer therapy. Cancers (Basel). 14(3906)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Liu DZ, Chang B, Li XD, Zhang QH and Zou
YH: MicroRNA-9 promotes the proliferation, migration, and invasion
of breast cancer cells via down-regulating FOXO1. Clin Transl
Oncol. 19:1133–1140. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Liu Y, Hua F, Zhan Y, Yang Y, Xie J, Cheng
Y and Li F: Carcinoma associated fibroblasts small extracellular
vesicles with low miR-7641 promotes breast cancer stemness and
glycolysis by HIF-1α. Cell Death Discov. 7(176)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chen B, Chan WN, Xie F, Mui CW, Liu X,
Cheung AHK, Lung RWM, Chow C, Zhang Z, Fang C, et al: The molecular
classification of cancer-associated fibroblasts on a pan-cancer
single-cell transcriptional atlas. Clin Transl Med.
13(e1516)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Labernadie A, Kato T, Brugués A,
Serra-Picamal X, Derzsi S, Arwert E, Weston A, González-Tarragó V,
Elosegui-Artola A, Albertazzi L, et al: A mechanically active
heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to
drive cancer cell invasion. Nat Cell Biol. 19:224–237.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Nurmik M, Ullmann P, Rodriguez F, Haan S
and Letellier E: In search of definitions: Cancer-associated
fibroblasts and their markers. Int J Cancer. 146:895–905.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ping Q, Yan R, Cheng X, Wang W, Zhong Y,
Hou Z, Shi Y, Wang C and Li R: Cancer-associated fibroblasts:
Overview, progress, challenges, and directions. Cancer Gene Ther.
28:984–999. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Shiga K, Hara M, Nagasaki T, Sato T,
Takahashi H and Takeyama H: Cancer-associated fibroblasts: Their
characteristics and their roles in tumor growth. Cancers (Basel).
7:2443–2458. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Jia C, Wang G, Wang T, Fu B, Zhang Y,
Huang L, Deng Y, Chen G, Wu X, Chen J, et al: Cancer-associated
fibroblasts induce epithelial-mesenchymal transition via the
transglutaminase 2-dependent IL-6/IL6R/STAT3 axis in hepatocellular
carcinoma. Int J Biol Sci. 16:2542–2558. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Long KB, Tooker G, Tooker E, Luque SL, Lee
JW, Pan X and Beatty GL: IL6 receptor blockade enhances
chemotherapy efficacy in pancreatic ductal adenocarcinoma. Mol
Cancer Ther. 16:1898–1908. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Sun Q, Zhang B, Hu Q, Qin Y, Xu W, Liu W,
Yu X and Xu J: The impact of cancer-associated fibroblasts on major
hallmarks of pancreatic cancer. Theranostics. 8:5072–5087.
2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Öhlund D, Handly-Santana A, Biffi G,
Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA,
Lee EJ, et al: Distinct populations of inflammatory fibroblasts and
myofibroblasts in pancreatic cancer. J Exp Med. 214:579–596.
2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Elyada E, Bolisetty M, Laise P, Flynn WF,
Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS,
et al: Cross-Species single-cell analysis of pancreatic ductal
adenocarcinoma reveals antigen-presenting cancer-associated
fibroblasts. Cancer Discov. 9:1102–1123. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Rhim AD, Oberstein PE, Thomas DH, Mirek
ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP,
Tattersall IW, et al: Stromal elements act to restrain, rather than
support, pancreatic ductal adenocarcinoma. Cancer Cell. 25:735–747.
2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mizutani Y, Kobayashi H, Iida T, Asai N,
Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, et al:
Meflin-positive cancer-associated fibroblasts inhibit pancreatic
carcinogenesis. Cancer Res. 79:5367–5381. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chen X and Song E: Turning foes to
friends: Targeting cancer-associated fibroblasts. Nat Rev Drug
Discov. 18:99–115. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Trams EG, Lauter CJ, Salem N Jr and Heine
U: Exfoliation of membrane ecto-enzymes in the form of
micro-vesicles. Biochim Biophys Acta. 645:63–70. 1981.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Becker A, Thakur BK, Weiss JM, Kim HS,
Peinado H and Lyden D: Extracellular vesicles in cancer:
Cell-to-cell mediators of metastasis. Cancer Cell. 30:836–848.
2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Sheehan C and D'Souza-Schorey C:
Tumor-derived extracellular vesicles: Molecular parcels that enable
regulation of the immune response in cancer. J Cell Sci.
132(jcs235085)2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
van Niel G, D'Angelo G and Raposo G:
Shedding light on the cell biology of extracellular vesicles. Nat
Rev Mol Cell Biol. 19:213–228. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Willms E, Cabañas C, Mäger I, Wood MJA and
Vader P: Extracellular vesicle heterogeneity: Subpopulations,
isolation techniques, and diverse functions in cancer progression.
Front Immunol. 9(738)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chang WH, Cerione RA and Antonyak MA:
Extracellular vesicles and their roles in cancer progression.
Methods Mol Biol. 2174:143–170. 2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Hessvik NP and Llorente A: Current
knowledge on exosome biogenesis and release. Cell Mol Life Sci.
75:193–208. 2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Latifkar A, Hur YH, Sanchez JC, Cerione RA
and Antonyak MA: New insights into extracellular vesicle biogenesis
and function. J Cell Sci. 132(jcs222406)2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Maas SLN, Breakefield XO and Weaver AM:
Extracellular vesicles: Unique intercellular delivery vehicles.
Trends Cell Biol. 27:172–188. 2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Zhang Y, Liu Y, Liu H and Tang WH:
Exosomes: Biogenesis, biologic function and clinical potential.
Cell Biosci. 9(19)2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Xie C, Ji N, Tang Z, Li J and Chen Q: The
role of extracellular vesicles from different origin in the
microenvironment of head and neck cancers. Mol Cancer.
18(83)2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mathieu M, Martin-Jaular L, Lavieu G and
Théry C: Specificities of secretion and uptake of exosomes and
other extracellular vesicles for cell-to-cell communication. Nat
Cell Biol. 21:9–17. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Tricarico C, Clancy J and D'Souza-Schorey
C: Biology and biogenesis of shed microvesicles. Small GTPases.
8:220–232. 2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Muralidharan-Chari V, Clancy JW, Sedgwick
A and D'Souza-Schorey C: Microvesicles: Mediators of extracellular
communication during cancer progression. J Cell Sci. 123:1603–1611.
2010.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Yáñez-Mó M, Siljander PRM, Andreu Z, Zavec
AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J,
et al: Biological properties of extracellular vesicles and their
physiological functions. J Extracell Vesicles.
4(27066)2015.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Clancy JW and D'Souza-Schorey C:
Tumor-derived extracellular vesicles: Multifunctional entities in
the tumor microenvironment. Annu Rev Pathol. 18:205–229.
2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Zhang Y, Liang F, Zhang D, Qi S and Liu Y:
Metabolites as extracellular vesicle cargo in health, cancer,
pleural effusion, and cardiovascular diseases: An emerging field of
study to diagnostic and therapeutic purposes. Biomed Pharmacother.
157(114046)2023.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Qin W and Dallas SL: Exosomes and
extracellular RNA in muscle and bone aging and crosstalk. Curr
Osteoporos Rep. 17:548–559. 2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Lee TH, Chennakrishnaiah S, Meehan B,
Montermini L, Garnier D, D'Asti E, Hou W, Magnus N, Gayden T,
Jabado N, et al: Barriers to horizontal cell transformation by
extracellular vesicles containing oncogenic H-ras. Oncotarget.
7:51991–52002. 2016.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Al-Nedawi K, Meehan B, Micallef J, Lhotak
V, May L, Guha A and Rak J: Intercellular transfer of the oncogenic
receptor EGFRvIII by microvesicles derived from tumour cells. Nat
Cell Biol. 10:619–624. 2008.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Skog J, Würdinger T, Van Rijn S, Meijer
DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky
AM and Breakefield XO: Glioblastoma microvesicles transport RNA and
proteins that promote tumour growth and provide diagnostic
biomarkers. Nat Cell Biol. 10:1470–1476. 2008.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Castillo-Sanchez R, Churruca-Schuind A,
Martinez-Ival M and Salazar EP: Cancer-associated fibroblasts
communicate with breast tumor cells through extracellular vesicles
in tumor development. Technol Cancer Res Treat.
21(15330338221131647)2022.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Drake CG, Jaffee E and Pardoll DM:
Mechanisms of immune evasion by tumors. Adv Immunol. 90:51–81.
2006.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Gajewski TF, Meng Y, Blank C, Brown I,
Kacha A, Kline J and Harlin H: Immune resistance orchestrated by
the tumor microenvironment. Immunol Rev. 213:131–145.
2006.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Piao YJ, Kim HS, Hwang EH, Woo J, Zhang M
and Moon WK: Breast cancer cell-derived exosomes and macrophage
polarization are associated with lymph node metastasis. Oncotarget.
9:7398–7410. 2017.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Clayton A and Tabi Z: Exosomes and the
MICA-NKG2D system in cancer. Blood Cells Mol Dis. 34:206–213.
2005.PubMed/NCBI View Article : Google Scholar
|
|
76
|
He C, Wang L, Li L and Zhu G:
Extracellular vesicle-orchestrated crosstalk between
cancer-associated fibroblasts and tumors. Transl Oncol.
14(101231)2021.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Cho JA, Park H, Lim EH and Lee KW:
Exosomes from breast cancer cells can convert adipose
tissue-derived mesenchymal stem cells into myofibroblast-like
cells. Int J Oncol. 40:130–138. 2012.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Li K, Liu T, Chen J, Ni H and Li W:
Survivin in breast cancer-derived exosomes activates fibroblasts by
up-regulating SOD1, whose feedback promotes cancer proliferation
and metastasis. J Biol Chem. 295:13737–13752. 2020.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Vu LT, Peng B, Zhang DX, Ma V,
Mathey-Andrews CA, Lam CK, Kiomourtzis T, Jin J, McReynolds L,
Huang L, et al: Tumor-secreted extracellular vesicles promote the
activation of cancer-associated fibroblasts via the transfer of
microRNA-125b. J Extracell Vesicles. 8(1599680)2019.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Dörsam B, Bösl T, Reiners KS, Barnert S,
Schubert R, Shatnyeva O, Zigrino P, Engert A, Hansen HP and von
Strandmann EP: Hodgkin lymphoma-derived extracellular vesicles
change the secretome of fibroblasts toward a CAF phenotype. Front
Immunol. 9(1358)2018.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Alamoudi AA, Alnoury A and Gad H: miRNA in
tumour metabolism and why could it be the preferred pathway for
energy reprograming. Brief Funct Genomics. 17:157–169.
2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Santos JM and Hussain F: Higher glucose
enhances breast cancer cell aggressiveness. Nutr Cancer.
72:734–746. 2020.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Sung JS, Kang CW, Kang S, Jang Y, Chae YC,
Kim BG and Cho NH: ITGB4-mediated metabolic reprogramming of
cancer-associated fibroblasts. Oncogene. 39:664–676.
2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Tao S, Li H, Ma X, Ma Y, He J, Gao Y and
Li J: Elevating microRNA-1-3p shuttled by cancer-associated
fibroblasts-derived extracellular vesicles suppresses breast cancer
progression and metastasis by inhibiting GLIS1. Cancer Gene Ther.
28:634–648. 2021.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Yang Y, Bucan V, Baehre H, Von Der Ohe J,
Otte A and Hass R: Acquisition of new tumor cell properties by
MSC-derived exosomes. Int J Oncol. 47:244–252. 2015.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Zhou W, Fong MY, Min Y, Somlo G, Liu L,
Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, et al:
Cancer-secreted miR-105 destroys vascular endothelial barriers to
promote metastasis. Cancer Cell. 25:501–515. 2014.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Bao Q, Huang Q, Chen Y, Wang Q, Sang R,
Wang L, Xie Y and Chen W: Tumor-derived extracellular vesicles
regulate cancer progression in the tumor microenvironment. Front
Mol Biosci. 8(796385)2022.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Mao X, Xu J, Wang W, Liang C, Hua J, Liu
J, Zhang B, Meng Q, Yu X and Shi S: Crosstalk between
cancer-associated fibroblasts and immune cells in the tumor
microenvironment: New findings and future perspectives. Mol Cancer.
20(131)2021.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Adib A, Sahu R, Mohta S, Pollock RE and
Casadei L: Cancer-derived extracellular vesicles: Their role in
sarcoma. Life (Basel). 12(481)2022.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Najafi M, Farhood B and Mortezaee K:
Extracellular matrix (ECM) stiffness and degradation as cancer
drivers. J Cell Biochem. 120:2782–2790. 2019.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Cosentino G, Romero-Cordoba S, Plantamura
I, Cataldo A and Iorio MV: miR-9-mediated inhibition of EFEMP1
contributes to the acquisition of pro-tumoral properties in normal
fibroblasts. Cells. 9(2143)2020.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Donnarumma E, Fiore D, Nappa M, Roscigno
G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C,
et al: Cancer-associated fibroblasts release exosomal microRNAs
that dictate an aggressive phenotype in breast cancer. Oncotarget.
8:19592–19608. 2017.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS,
Yan YR, Song FY, Wang FF, Zhu XH, Liao WJ, et al: CAFs secreted
exosomes promote metastasis and chemotherapy resistance by
enhancing cell stemness and epithelial-mesenchymal transition in
colorectal cancer. Mol Cancer. 18(91)2019.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Josson S, Gururajan M, Sung SY, Hu P, Shao
C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, et al: Stromal
fibroblast-derived miR-409 promotes epithelial-to-mesenchymal
transition and prostate tumorigenesis. Oncogene. 34:2690–2699.
2015.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Ratti M, Lampis A, Ghidini M, Salati M,
Mirchev MB, Valeri N and Hahne JC: MicroRNAs (miRNAs) and long
non-coding RNAs (lncRNAs) as new tools for cancer therapy: First
steps from bench to bedside. Target Oncol. 15:261–278.
2020.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Pang W, Su J, Wang Y, Feng H, Dai X, Yuan
Y, Chen X and Yao W: Pancreatic cancer-secreted miR-155 implicates
in the conversion from normal fibroblasts to cancer-associated
fibroblasts. Cancer Sci. 106:1362–1369. 2015.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Yoshii S, Hayashi Y, Iijima H, Inoue T,
Kimura K, Sakatani A, Nagai K, Fujinaga T, Hiyama S, Kodama T, et
al: Exosomal microRNAs derived from colon cancer cells promote
tumor progression by suppressing fibroblast TP53 expression. Cancer
Sci. 110:2396–2407. 2019.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Urciuoli E, Giorda E, Scarsella M, Petrini
S and Peruzzi B: Osteosarcoma-derived extracellular vesicles induce
a tumor-like phenotype in normal recipient cells. J Cell Physiol.
233:6158–6172. 2018.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Hu T and Hu J: Melanoma-derived exosomes
induce reprogramming fibroblasts into cancer-associated fibroblasts
via Gm26809 delivery. Cell Cycle. 18:3085–3094. 2019.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Carles-Fontana R, Heaton N, Palma E and
Khorsandi S: Extracellular vesicle-mediated mitochondrial
reprogramming in cancer. Cancers (Basel). 14(1865)2022.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Fridman ES, Ginini L and Gil Z: The role
of extracellular vesicles in metabolic reprogramming of the tumor
microenvironment. Cells. 11(1433)2022.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Chen G, Huang AC, Zhang W, Zhang G, Wu M,
Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1
contributes to immunosuppression and is associated with anti-PD-1
response. Nature. 560:382–386. 2018.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Poggio M, Hu T, Pai CC, Chu B, Belair CD,
Chang A, Montabana E, Lang UE, Fu Q, Fong L and Blelloch R:
Suppression of exosomal PD-L1 induces systemic anti-tumor immunity
and memory. Cell. 177:414–427.e13. 2019.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud
AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C,
et al: Immune evasion mediated by PD-L1 on glioblastoma-derived
extracellular vesicles. Sci Adv. 4(eaar2766)2018.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Feng R, Li Z, Ge G, Wang C, Jia Y and
Ouyang J: Cancer-associated fibroblast-derived extracellular
vesicles mediate immune escape of bladder cancer via PD-L1/PD-1
expression. Endocr Metab Immune Disord Drug Targets. 23:1410–1420.
2023.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Yang J, Chen J, Liang H and Yu Y:
Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+
T-cell activity and promotes immune escape. Cancer Sci.
113:3044–3054. 2022.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Chowdhury R, Webber JP, Gurney M, Mason
MD, Tabi Z and Clayton A: Cancer exosomes trigger mesenchymal stem
cell differentiation into pro-angiogenic and pro-invasive
myofibroblasts. Oncotarget. 6:715–731. 2015.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Ringuette Goulet C, Bernard G, Tremblay S,
Chabaud S, Bolduc S and Pouliot F: Exosomes induce fibroblast
differentiation into cancer-associated fibroblasts through TGFβ
signaling. Mol Cancer Res. 16:1196–1204. 2018.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Webber JP, Spary LK, Sanders AJ, Chowdhury
R, Jiang WG, Steadman R, Wymant J, Jones AT, Kynaston H, Mason MD,
et al: Differentiation of tumour-promoting stromal myofibroblasts
by cancer exosomes. Oncogene. 34:290–302. 2015.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Webber J, Steadman R, Mason MD, Tabi Z and
Clayton A: Cancer exosomes trigger fibroblast to myofibroblast
differentiation. Cancer Res. 70:9621–9630. 2010.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Wei M, Yang T, Chen X, Wu Y, Deng X, He W,
Yang J and Wang Z: Malignant ascites-derived exosomes promote
proliferation and induce carcinoma-associated fibroblasts
transition in peritoneal mesothelial cells. Oncotarget.
8:42262–42271. 2017.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Yeon JH, Jeong HE, Seo H, Cho S, Kim K, Na
D, Chung S, Park J, Choi N and Kang JY: Cancer-derived exosomes
trigger endothelial to mesenchymal transition followed by the
induction of cancer-associated fibroblasts. Acta Biomater.
76:146–153. 2018.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Lin Z, Li G, Jiang K, Li Z and Liu T:
Cancer therapy resistance mediated by cancer-associated
fibroblast-derived extracellular vesicles: Biological mechanisms to
clinical significance and implications. Mol Cancer.
23(191)2024.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Musi A and Bongiovanni L: Extracellular
vesicles in cancer drug resistance: Implications on melanoma
therapy. Cancers (Basel). 15(1074)2023.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Federspiel J, Dudas J, Hofauer BG,
Wollenberg B and Steinbichler TB: Cancer-associated
fibroblasts-derived exosomes as mediators of immunotherapy
resistance in head and neck squamous cell carcinoma. Cells.
14(1978)2025.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Yang C, Zhang Y, Yan M, Wang J, Wang J,
Wang M, Xuan Y, Cheng H, Ma J, Chai C, et al: Exosomes derived from
cancer-associated fibroblasts promote tumorigenesis, metastasis and
chemoresistance of colorectal cancer by upregulating circ_0067557
to target Lin28. BMC Cancer. 24(64)2024.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Singh M, Tiwari PK, Kashyap V and Kumar S:
Proteomics of extracellular vesicles: Recent updates, challenges
and limitations. Proteomes. 13(12)2025.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Hoshino A, Costa-Silva B, Shen TL,
Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di
Giannatale A, Ceder S, et al: Tumour exosome integrins determine
organotropic metastasis. Nature. 527:329–335. 2015.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Andreu Z and Yáñez-Mó M: Tetraspanins in
extracellular vesicle formation and function. Front Immunol.
5(442)2014.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Li I and Nabet BY: Exosomes in the tumor
microenvironment as mediators of cancer therapy resistance. Mol
Cancer. 18(32)2019.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Naito Y, Yoshioka Y, Yamamoto Y and Ochiya
T: How cancer cells dictate their microenvironment: Present roles
of extracellular vesicles. Cell Mol Life Sci. 74:697–713.
2017.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Kalluri R and LeBleu VS: The biology,
function, and biomedical applications of exosomes. Science.
367(eaau6977)2020.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Nazarenko I, Rana S, Baumann A, McAlear J,
Hellwig A, Trendelenburg M, Lochnit G, Preissner KT and Zöller M:
Cell surface tetraspanin Tspan8 contributes to molecular pathways
of exosome-induced endothelial cell activation. Cancer Res.
70:1668–1678. 2010.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Fang H, Dai W, Gu R, Zhang Y, Li J, Luo W,
Tong S, Han L, Wang Y, Jiang C, et al: myCAF-derived exosomal PWAR6
accelerates CRC liver metastasis via altering glutamine
availability and NK cell function in the tumor microenvironment. J
Hematol Oncol. 17(126)2024.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Peng Z, Tong Z, Ren Z, Ye M and Hu K:
Cancer-associated fibroblasts and its derived exosomes: A new
perspective for reshaping the tumor microenvironment. Mol Med.
29(66)2023.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Gou Z, Li J, Liu J and Yang N: The hidden
messengers: Cancer associated fibroblasts-derived exosomal miRNAs
as key regulators of cancer malignancy. Front Cell Dev Biol.
12(1378302)2024.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Chen WQ, Chen KX, He YT, Jia WH, Liu ZH,
Ma HX, Miao XP, Pan KF, Wu C, Xia CF, et al: Expert consensus on
liquid biopsy-based multi-cancer early detection (2025 edition).
Zhonghua Zhong Liu Za Zhi. 47:558–574. 2025.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
128
|
Chang L, Li J and Zhang R: Liquid biopsy
for early diagnosis of non-small cell lung carcinoma: Recent
research and detection technologies. Biochim Biophys Acta Rev
Cancer. 1877(188729)2022.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Bao H, Min L, Bu F, Wang S and Meng J:
Recent advances of liquid biopsy: Interdisciplinary strategies
toward clinical decision-making. Interdiscip Med.
1(e20230021)2023.
|
|
130
|
Marrugo-Ramírez J, Mir M and Samitier J:
Blood-Based cancer biomarkers in liquid biopsy: A promising
non-invasive alternative to tissue biopsy. Int J Mol Sci.
19(2877)2018.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Shai S, Patolsky F, Drori H, Scheinman EJ,
Davidovits E, Davidovits G, Tirman S, Arber N, Katz A and Adir Y: A
novel, accurate, and non-invasive liquid biopsy test to measure
cellular immune responses as a tool to diagnose early-stage lung
cancer: A clinical trials study. Respir Res. 24(52)2023.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Akers JC, Ramakrishnan V, Kim R, Skog J,
Nakano I, Pingle S, Kalinina J, Hua W, Kesari S, Mao Y, et al:
MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid
(CSF): A platform for glioblastoma biomarker development. PLoS One.
8(e78115)2013.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Arraud N, Linares R, Tan S, Gounou C,
Pasquet JM, Mornet S and Brisson AR: Extracellular vesicles from
blood plasma: Determination of their morphology, size, phenotype
and concentration. J Thromb Haemost. 12:614–627. 2014.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Van Der Pol E, Böing AN, Harrison P, Sturk
A and Nieuwland R: Classification, functions, and clinical
relevance of extracellular vesicles. Pharmacol Rev. 64:676–705.
2012.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Costa A, Kieffer Y, Scholer-Dahirel A,
Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L,
Bernard C, et al: Fibroblast heterogeneity and immunosuppressive
environment in human breast cancer. Cancer Cell. 33:463–479.e10.
2018.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Zhang H and Lyden D: Asymmetric-flow
field-flow fractionation technology for exomere and small
extracellular vesicle separation and characterization. Nat Protoc.
14:1027–1053. 2019.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Hannon G, Lysaght J, Liptrott NJ and
Prina-Mello A: Immunotoxicity considerations for next generation
cancer nanomedicines. Adv Sci (Weinh). 6(1900133)2019.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Tibbitt MW, Dahlman JE and Langer R:
Emerging frontiers in drug delivery. J Am Chem Soc. 138:704–717.
2016.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Kamerkar S, LeBleu VS, Sugimoto H, Yang S,
Ruivo CF, Melo SA, Lee JJ and Kalluri R: Exosomes facilitate
therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Nature. 546:498–503. 2017.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Debela DT, Muzazu SG, Heraro KD, Ndalama
MT, Mesele BW, Haile DC, Kitui SK and Manyazewal T: New approaches
and procedures for cancer treatment: Current perspectives. SAGE
Open Med. 9(20503121211034366)2021.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Datta M, Coussens LM, Nishikawa H, Hodi FS
and Jain RK: Reprogramming the tumor microenvironment to improve
immunotherapy: Emerging strategies and combination therapies. Am
Soc Clin Oncol Educ Book. 39:165–174. 2019.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Jarosz-Biej M, Smolarczyk R, Cichoń T and
Szala S: Reprogramming of tumor microenvironment in therapy. In:
Cancer Immunology. Rezaei N (ed). Springer International
Publishing, Cham, pp403-412, 2021.
|
|
143
|
Hu M and Huang L: Strategies targeting
tumor immune and stromal microenvironment and their clinical
relevance. Adv Drug Deliv Rev. 183(114137)2022.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Nedaeinia R, Najafgholian S, Salehi R,
Goli M, Ranjbar M, Nickho H, Haghjooy Javanmard S, A Ferns G and
Manian M: The role of cancer-associated fibroblasts and exosomal
miRNAs-mediated intercellular communication in the tumor
microenvironment and the biology of carcinogenesis: A systematic
review. Cell Death Discov. 10(380)2024.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Lakins MA, Ghorani E, Munir H, Martins CP
and Shields JD: Cancer-associated fibroblasts induce
antigen-specific deletion of CD8 + T Cells to protect
tumour cells. Nat Commun. 9(948)2018.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Geng X, Chen H, Zhao L, Hu J, Yang W, Li
G, Cheng C, Zhao Z, Zhang T, Li L and Sun B: Cancer-associated
fibroblast (CAF) heterogeneity and targeting therapy of CAFs in
pancreatic cancer. Front Cell Dev Biol. 9(655152)2021.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Guo T and Xu J: Cancer-associated
fibroblasts: A versatile mediator in tumor progression, metastasis,
and targeted therapy. Cancer Metastasis Rev. 43:1095–1116.
2024.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Badran O, Cohen I and Bar-Sela G:
Cancer-associated fibroblasts in solid tumors and sarcomas:
Heterogeneity, function, and therapeutic implications. Cells.
14(1398)2025.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Ritter A, Hoock SC, Kreis NN, Roth S,
Torres Colin RC, Friemel A, Wildner JM, Scherr I, Louwen F, Solbach
C and Yuan J: Obesity- and tumor-derived signals drive
cancer-associated state transitions in breast mesenchymal
stromal/stem cells reprogrammed by IL1RA or JAK inhibition. Exp
Hematol Oncol. 15(16)2026.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Lau NCH and Yam JWP: From exosome
biogenesis to absorption: Key takeaways for cancer research.
Cancers (Basel). 15(1992)2023.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Sinha D, Roy S, Saha P, Chatterjee N and
Bishayee A: Trends in research on exosomes in cancer progression
and anticancer therapy. Cancers (Basel). 13(326)2021.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Mortezaee K and Majidpoor J: An update of
extracellular vesicle involvement in different steps of cancer
metastasis and targeting strategies. Curr Med Chem. 31:4495–4509.
2024.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Sun H, Burrola S, Wu J and Ding WQ:
Extracellular vesicles in the development of cancer therapeutics.
Int J Mol Sci. 21(6097)2020.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Xiao S, Chen L, Chen Z and Li Q:
Therapeutically harnessing tumor cell-derived extracellular
vesicles for multiple myeloma: Recent advances and future
perspectives. Pharmaceutics. 16(1439)2024.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Datta A, Kim H, McGee L, Johnson AE,
Talwar S, Marugan J, Southall N, Hu X, Lal M, Mondal D, et al:
High-throughput screening identified selective inhibitors of
exosome biogenesis and secretion: A drug repurposing strategy for
advanced cancer. Sci Rep. 8(8161)2018.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Trajkovic K, Hsu C, Chiantia S, Rajendran
L, Wenzel D, Wieland F, Schwille P, Brügger B and Simons M:
Ceramide triggers budding of exosome vesicles into multivesicular
endosomes. Science. 319:1244–1247. 2008.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Christianson HC, Svensson KJ, Van
Kuppevelt TH, Li JP and Belting M: Cancer cell exosomes depend on
cell-surface heparan sulfate proteoglycans for their
internalization and functional activity. Proc Natl Acad Sci USA.
110:17380–17385. 2013.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Wortzel I, Dror S, Kenific CM and Lyden D:
Exosome-mediated metastasis: Communication from a distance. Dev
Cell. 49:347–360. 2019.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Xin L, Gao J, Zheng Z, Chen Y, Lv S, Zhao
Z, Yu C, Yang X and Zhang R: Fibroblast Activation protein-α as a
target in the bench-to-bedside diagnosis and treatment of tumors: A
narrative review. Front Oncol. 11(648187)2021.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Fang J, Xiao L, Joo K, Liu Y, Zhang C, Liu
S, Conti PS, Li Z and Wang P: A potent immunotoxin targeting
fibroblast activation protein for treatment of breast cancer in
mice. Int J Cancer. 138:1013–1023. 2016.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Ostermann E, Garin-Chesa P, Heider KH,
Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ and Adolf GR:
Effective immunoconjugate therapy in cancer models targeting a
serine protease of tumor fibroblasts. Clin Cancer Res.
14:4584–4592. 2008.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Duperret EK, Trautz A, Ammons D,
Perales-Puchalt A, Wise MC, Yan J, Reed C and Weiner DB: Alteration
of the tumor stroma using a consensus DNA vaccine targeting
fibroblast activation protein (FAP) synergizes with antitumor
vaccine therapy in mice. Clin Cancer Res. 24:1190–1201.
2018.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Wang LCS, Lo A, Scholler J, Sun J,
Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC,
et al: Targeting fibroblast activation protein in tumor stroma with
chimeric antigen receptor T cells can inhibit tumor growth and
augment host immunity without severe toxicity. Cancer Immunol Res.
2:154–166. 2014.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Roberts EW, Deonarine A, Jones JO, Denton
AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, et
al: Depletion of stromal cells expressing fibroblast activation
protein-α from skeletal muscle and bone marrow results in cachexia
and anemia. J Exp Med. 210:1137–1151. 2013.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Pietras K, Pahler J, Bergers G and Hanahan
D: Functions of paracrine PDGF signaling in the proangiogenic tumor
stroma revealed by pharmacological targeting. PLoS Med.
5(e19)2008.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Sherman MH, Yu RT, Engle DD, Ding N,
Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S,
et al: Vitamin D receptor-mediated stromal reprogramming suppresses
pancreatitis and enhances pancreatic cancer therapy. Cell.
159:80–93. 2014.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Jalilian E, Abolhasani-Zadeh F, Afgar A,
Samoudi A, Zeinalynezhad H and Langroudi L: Neutralizing
tumor-related inflammation and reprogramming of cancer-associated
fibroblasts by Curcumin in breast cancer therapy. Sci Rep.
13(20770)2023.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Hofheinz RD, al-Batran SE, Hartmann F,
Hartung G, Jäger D, Renner C, Tanswell P, Kunz U, Amelsberg A,
Kuthan H and Stehle G: Stromal antigen targeting by a humanised
monoclonal antibody: An early phase II trial of sibrotuzumab in
patients with metastatic colorectal cancer. Onkologie. 26:44–48.
2003.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Moss RA, Moore D, Mulcahy MF, Nahum K,
Saraiya B, Eddy S, Kleber M and Poplin EA: A multi-institutional
phase 2 study of imatinib mesylate and gemcitabine for first-line
treatment of advanced pancreatic cancer. Gastrointest Cancer Res.
5:77–83. 2012.PubMed/NCBI
|
|
170
|
Grierson PM, Suresh R, Tan B, Pedersen KS,
Amin M, Park H, Trikalinos NA, Liu J, Boice N, Brown A, et al: A
pilot study of paricalcitol plus nanoliposomal irinotecan and
5-FU/LV in advanced pancreatic cancer patients after progression on
gemcitabine-based therapy. Clin Cancer Res. 29:4733–4739.
2023.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Chung V, Alistar A, Becerra C, Kasi A,
Borazanci E, Jameson GS, Roe DJ, Wertheim BC, Cridebring D, Truitt
M, et al: Pembrolizumab ± paricalcitol in metastatic pancreatic
cancer postmaximal cytoreduction. Oncologist.
30(oyae323)2025.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Weiss GJ, Blaydorn L, Beck J,
Bornemann-Kolatzki K, Urnovitz H, Schütz E and Khemka V: Phase
Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in
metastatic pancreatic adenocarcinoma. Invest New Drugs. 36:96–102.
2018.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Bockorny B, Semenisty V, Macarulla T,
Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ,
Pedersen KS, et al: BL-8040, a CXCR4 antagonist, in combination
with pembrolizumab and chemotherapy for pancreatic cancer: The
COMBAT trial. Nat Med. 26:878–885. 2020.PubMed/NCBI View Article : Google Scholar
|
